The Welsh government and Vertex Pharmaceuticals have reached an agreement that will allow access to the company’s Kaftrio (ivacaftor/tezacaftor/elexacaftor) for cystic fibrosis (CF) patients as soon as the medication is approved in Europe. Kaftrio is a triple combination therapy for the treatment of CF, designed to…
News
ContraFect has been awarded to $18.9 million by the nonprofit investment group CARB-X to advance CF-370 as a potential treatment for Pseudomonas aeruginosa infections. These bacteria and the thick layer of biofilm they produce are a major cause of pulmonary exacerbations in cystic fibrosis (CF) patients. CARB-X, which stands for…
Levels of inflammatory markers in the lungs may help predict pulmonary exacerbations in children with cystic fibrosis (CF), a new study suggests. The study, “BAL inflammatory markers can predict pulmonary exacerbations in children with cystic fibrosis,” was published in the journal Chest. In people…
Trikafta (elexacaftor/tezacaftor/ivacaftor combo) improves lung function in cystic fibrosis (CF) patients who have one F508del mutation and either one gating mutation (F/G) or one residual function mutation (F/RF) in the CFTR gene, new clinical trial data show. That finding was announced by Vertex Pharmaceuticals, which markets Trikafta.
Measuring levels of a molecule called lipoarabinomannan, or LAM, in a person’s urine could be an easier way of screening for airway infections due to nontuberculous mycobacteria in people with cystic fibrosis (CF), a study suggests. The study, “Urine lipoarabinomannan as a marker for low-risk…
Scientists have discovered that Vav3, a protein that is over-produced in the lining of the lungs of people with cystic fibrosis (CF), promotes lung infections by creating a “docking station” that bacteria such as Pseudomonas aeruginosa use to attach themselves to the lungs. Finding a way to inhibit…
A new technology could enable faster and more accurate cystic fibrosis (CF) diagnoses by non-invasively tracking the movement of air through even the fine structures of the lungs at high-resolution. A study done in mice showed this technology, called X-ray velocimetry (XV), could pinpoint localized areas of abnormal airflow…
Patient dosing has begun in a Phase 1b trial evaluating Calithera Bioscience’s oral therapy CB-280 for cystic fibrosis (CF) patients with chronic airway infections, the company announced. The study (NCT04279769), currently enrolling eligible adults at its two U.S. sites, will test four escalating…
The number of adults with cystic fibrosis (CF) living in the U.K. is expected to increase by at least 28% in 10 years, and 36% of these adults will be older than 40, a study projects. Findings highlight the need to make plans now to care for this changing…
A five-year, $3.2 million grant from the National Institutes of Health (NIH) will fund a research project that aims to better understand the interactions between bacteria and mucus. Results could help inform new ways of treating diseases where bacterial infections that involve mucus are problematic, such as cystic…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.